SCHEMBL1282185

SCHEMBL1282185

COC(=O)c1cc(N2CCOCC2)cc2nc(C(F)(F)F)[nH]c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.43
KDM4E B2RXH2 3/20 0.43
LMNA P02545 1/20 0.43
HTT P42858 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAPT P10636 2/20 0.41
MEN1 O00255 2/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
ALOX15 P16050 1/20 0.40
LRRK2 Q5S007 1/20 0.39
APAF1 O14727 1/20 0.39
TDP2 O95551 1/20 0.39
NSD2 O96028 1/20 0.39
PLA2G1B P04054 1/20 0.39
HSP90AA1 P07900 1/20 0.39
PLCG1 P19174 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20578257 0.87 PIK3C2B (0.43) ALDH1A1KDM4EL3MBTL1MAPTMEN1
SCHEMBL1281782 0.84 MAPT (0.47) ALDH1A1KDM4ELMNAHTTL3MBTL1
SCHEMBL1281793 0.84 NPC1 (0.42) ALDH1A1KDM4EMAPTMEN1NPC1
SCHEMBL1688037 0.84 ALDH1A1 (0.44) ALDH1A1KDM4ELMNAHTTL3MBTL1
SCHEMBL1282463 0.84 MAPT (0.43) ALDH1A1KDM4EMAPTMEN1NPC1
SCHEMBL1281993 0.74 PDE3B (0.44) ALDH1A1MAPTMEN1NPC1RAB9A
SCHEMBL27903995 0.74 KDM4E (0.35) ALDH1A1KDM4EL3MBTL1MAPTMEN1
SCHEMBL1632059 0.73 PRKDC (0.44) ALDH1A1KDM4EMAPTALOX15PIK3CB
SCHEMBL1632944 0.72 ALDH1A1 (0.47) ALDH1A1KDM4EMAPTMEN1NPC1
SCHEMBL27921643 0.72 KDM4E (0.51) KDM4ESMN1; SMN2PIK3CBPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3170813-B1 BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2018-12-12 EP claimed
EP-3170813-A1 BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS Glaxosmithkline LLC (US) 2017-05-24 EP claimed
US-8435988-B2 Benzimidazole derivatives as P13 kinase inhibitors GLAXOSMITHKLINE LLC (US) 2013-05-07 US claimed
US-20120088767-A1 BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC 2012-04-12 US claimed
US-10660898-B2 Benzimidazole derivatives as PI3 kinase inhibitors GLAXOSMITHKLINE LLC (US) 2020-05-26 US disclosed
US-20190255064-A1 BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC 2019-08-22 US disclosed
US-10314845-B2 Benzimidazole derivatives as PI3 kinase inhibitors GLAXOSMITHKLINE LLC (US) 2019-06-11 US disclosed
EP-3170813-B1 BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2018-12-12 EP disclosed
US-20180263994-A1 Benzimidazole Derivatives as PI3 Kinase Inhibitors GLAXOSMITHKLINE LLC 2018-09-20 US disclosed
US-9872860-B2 Benzimidazole derivatives as PI3 kinase inhibitors GLAXOSMITHKLINE LLC (US) 2018-01-23 US disclosed
EP-3170813-A1 BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS Glaxosmithkline LLC (US) 2017-05-24 EP disclosed
US-20170112844-A1 Benzimidazole Derivatives As PI3 Kinase Inhibitors GLAXOSMITHKLINE LLC 2017-04-27 US disclosed
US-20140018534-A1 Benzimidazole Derivatives As PI3 Kinase Inhibitors GLAXOSMITHKLINE LLC (US) 2014-01-16 US disclosed
US-8541411-B2 Benzimidazole derivatives as PI3 kinase inhibitors GLAXOSMITHKLINE LLC (US) 2013-09-24 US disclosed
EP-2624696-A1 BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS GlaxoSmithKline LLC (US) 2013-08-14 EP disclosed
US-20130196990-A1 Benzimidazole Derivatives As PI3 Kinase Inhibitors GLAXOSMITHKLINE LLC 2013-08-01 US disclosed
US-20130197221-A1 Benzimidazole Derivatives As PI3 Kinase Inhibitors GLAXOSMITHKLINE LLC (US) 2013-08-01 US disclosed
US-8435988-B2 Benzimidazole derivatives as P13 kinase inhibitors GLAXOSMITHKLINE LLC (US) 2013-05-07 US disclosed
US-20120088767-A1 BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC 2012-04-12 US disclosed
WO-2012047538-A1 BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2012-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170112844-A1 Benzimidazole Derivatives As PI3 Kinase Inhibitors PI4KB, PIK3CD, PI4KA ALDH1A1 1375/4885KDM4E 2969/4885LMNA 4753/4885
US-20180263994-A1 Benzimidazole Derivatives as PI3 Kinase Inhibitors PI4KB, PIK3CD, PI4KA ALDH1A1 1375/4885KDM4E 2969/4885LMNA 4753/4885
US-20140018534-A1 Benzimidazole Derivatives As PI3 Kinase Inhibitors PI4KB, PIK3CD, PI4KA ALDH1A1 1428/4885KDM4E 2943/4885LMNA 4759/4885
US-20120088767-A1 BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS PI4KB, PI4KA, PIK3CD ALDH1A1 1291/4885KDM4E 2861/4885LMNA 4764/4885
US-10660898-B2 Benzimidazole derivatives as PI3 kinase inhibitors PI4KB, PIK3CD, PI4KA ALDH1A1 1375/4885KDM4E 2969/4885LMNA 4753/4885
US-20130196990-A1 Benzimidazole Derivatives As PI3 Kinase Inhibitors PI4KB, PIK3CD, PI4KA ALDH1A1 1375/4885KDM4E 2969/4885LMNA 4753/4885
US-10314845-B2 Benzimidazole derivatives as PI3 kinase inhibitors PI4KB, PIK3CD, PI4KA ALDH1A1 1375/4885KDM4E 2969/4885LMNA 4753/4885
US-20130197221-A1 Benzimidazole Derivatives As PI3 Kinase Inhibitors PI4KB, PIK3CD, PI4KA ALDH1A1 1375/4885KDM4E 2969/4885LMNA 4753/4885
US-20190255064-A1 BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS PI4KB, PIK3CD, PI4KA ALDH1A1 1375/4885KDM4E 2969/4885LMNA 4753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.